Kv1.1 is the protein encoded by KCNA1, a voltage-gated potassium channel alpha subunit in the Kv1 (Shaker-related) family.[1][2] Kv1.1 participates in action-potential repolarization, spike-frequency control, and axonal excitability tuning across central and peripheral circuits. In disease biology, Kv1.1 dysfunction is strongly linked to episodic ataxia and related hyperexcitability syndromes, and it remains relevant to neurodegeneration as an excitability and network-stability node.[3][4]
Kv1.1 has the canonical six-transmembrane topology (S1-S6) with a pore loop between S5 and S6. Functional channels form tetramers and often include heteromeric Kv1 partners and cytosolic accessory subunits that modify kinetics and trafficking.[1:1][2:1]
Key structural features:
This architecture enables fast voltage-dependent gating suited for millisecond-scale control of neuronal firing.
Kv1.1 contributes outward potassium current during and after depolarization, preventing runaway repetitive firing and preserving signal precision.[1:2][5]
At axonal and juxtaparanodal regions, Kv1-family channels shape conduction reliability and transmitter release dynamics. This timing control is critical in cerebellar and corticothalamic circuits where small excitability shifts can produce large systems-level symptoms.[3:1][4:1]
When neuronal metabolism is impaired or inflammatory signaling rises, potassium-channel reserve becomes even more important. Kv1.1 dysfunction can lower resilience thresholds and increase susceptibility to network instability, seizures, and maladaptive plasticity.[4:2][6]
Pathogenic KCNA1/Kv1.1 variants are a well-established cause of episodic ataxia type 1 (EA1), often with myokymia and peripheral nerve hyperexcitability. Disease phenotypes arise primarily from altered gating or reduced functional current, producing hyperexcitable motor circuits.[3:2][7]
Kv1.1 channel dysfunction can contribute to seizure susceptibility through impaired repolarization reserve and abnormal synchronization. This supports the broader concept that potassium-channel instability can accelerate neural system fragility in mixed pathologies.[4:3][6:1]
Kv1.1 is not a primary monogenic cause of AD/PD, but it remains mechanistically relevant as a circuit-stability regulator linked to:
This modifier framing is useful in precision models where excitability burden interacts with proteostasis and inflammatory load.[4:4][6:2][8]
Clinical management in KCNA1-associated channelopathy has historically used anti-excitability agents (for example carbamazepine or acetazolamide in selected phenotypes), but response heterogeneity is common.[7:1] For neurodegeneration translation, key priorities are biomarker-defined subgrouping and safer channel-specific modulation strategies.
Important translational questions:
Jan LY, Jan YN. Voltage-gated potassium channels and the diversity of electrical signalling. Journal of Physiology. 2012. ↩︎ ↩︎ ↩︎
Gutman GA, Chandy KG, Grissmer S, et al. International Union of Pharmacology. LIII. Nomenclature and molecular relationships of voltage-gated potassium channels. Pharmacological Reviews. 2005. ↩︎ ↩︎
Browne DL, Gancher ST, Nutt JG, et al. Episodic ataxia/myokymia syndrome is associated with point mutations in the human potassium channel gene, KCNA1. Nature Genetics. 1994. ↩︎ ↩︎ ↩︎
Glasscock E, Yoo JW, Chen TT, Klassen TL, Noebels JL. Kv1.1 potassium channel deficiency reveals brain-driven cardiac dysfunction as a candidate mechanism for sudden unexplained death in epilepsy. Journal of Neuroscience. 2010. ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Vacher H, Mohapatra DP, Trimmer JS. Localization and targeting of voltage-dependent ion channels in mammalian central neurons. Physiological Reviews. 2008. ↩︎
Chandy KG, Norton RS. Peptide blockers of Kv1 channels in autoimmune and neuroinflammatory disease. Toxicon. 2017. ↩︎ ↩︎ ↩︎
Zuberi SM, Eunson LH, Spauschus A, et al. A novel mutation in the human voltage-gated potassium channel gene KCNA1 associates with episodic ataxia type 1 and sometimes partial epilepsy. Brain. 1999. ↩︎ ↩︎
Surmeier DJ, Obeso JA, Halliday GM. Selective neuronal vulnerability in Parkinson disease. Nature Reviews Neuroscience. 2017. ↩︎